CardioSignal and academic collaborators conclude a heart failure study testing the performance of mobile-based motion sensor technology
The study of >1000 patients reached its primary endpoint of recognizing clinical heart failure with smartphone-based technology. Comprehensive results of the study will be published later in 2022.
The study found evidence that a one-minute assessment of heart motion with a smartphone equipped with micro-electro-mechanical motion sensors (accelerometer, gyroscope) can recognize heart failure with at least the same performance as existing clinical methods. Reliable heart disease detection tools that can be accessed with a smartphone have the potential to significantly improve the assessment of patients with suspected heart failure through earlier detection leading to improved screening and care.
“The ability to have individuals be able to use their own smartphone to quickly and effectively evaluate heart function potentially represents a transformation of screening for heart failure,” says Professor Kenneth Mahaffey, a cardiologist at Stanford University.
Heart failure (HF) is a chronic condition in which the heart is unable to pump or fill adequately to meet the circulatory needs of the body. In the United States alone, it affects more than 6 million people. The disease is hard to diagnose as >30% of patients receive their first heart failure diagnosis when hospitalized for the condition, despite having symptoms often for months or years. Heart failure is a major health burden, being responsible for EUR 29 (1) billion in healthcare costs in the EU and $40 billion (2) in the US, with numbers expected to rise.
“Heart failure is the leading cause of hospitalization for people over 65 but very challenging to diagnose, which leads to delayed treatment and worse outcomes for patients (3,4). With this study, we took a major leap in finding evidence to support an accessible, scalable and reliable digital biomarker for heart failure. It is a major milestone in our mission to improve heart health globally and offer technological solutions that could lower the cost of healthcare and improve outcomes at the same time,” says CardioSignal’s CEO, cardiologist Juuso Blomster.
Results of the study will include a comparison between the heart failure cohort and a control group for individuals without signs of, diagnosed, or suspected heart failure.
The study in summary:
Carried out in United States and Europe in 2019-2022
Aimed to validate heart failure-specific characteristics obtained with accelerometer and gyroscope to detect clinical heart failure
The study included >1000 individuals, including controls and patients with heart failure, hospitalized either for heart failure with preserved ejection fraction (HFpEF) or reduced ejection fraction (HFrEF)
Comprehensive results will be published later in 2022
Further information:
CardioSignal
Juuso Blomster, CEO, juuso.blomster@cardiosignal.com
Juulia Simonen (Communications) juulia.simonen@cardiosignal.com, tel. +358503059018
About CardioSignal
We develop groundbreaking solutions for the detection of heart diseases with digital cardiac biomarkers. CardioSignal is a mobile application and a medical device that utilizes motion sensor technology to non-invasively measure cardiac motion and function. Originally an academic spinoff, the company’s patented technology is built on a decade of research and algorithm development. CardioSignal is a brand and a product by Precordior. www.cardiosignal.com
1. Cook, C. et al. The annual global economic burden of heart failure. Int J Cardiol 171, 368-375 (2014)
2. Voigt J, et al. A reevaluation of the costs of heart failure and its implications for allocation of health resources in the United States. Clin Cardiol. 2014 May;37(5):312-21.
3. Azad N, et al. Management of chronic heart failure in the older population. J Geriatr Cardiol. 2014;11(4):329-337.
4. Alexander T. Sandhu et al, Disparity in the Setting of Incident Heart Failure Diagnosis, Circulation: Heart Failure (2021); vol. 14, No. 8.
